CRSP CRISPR Therapeutics AG - Common Shares
$52,78
Harga · Agu 18, 2026
Fundamental per Agu 3, 2026
Rentang 52M
$44–$78
25% of range
Peringkat Analis
HOLD
29 analysts
Target Harga
$88
+66% upside
P/E (TTM)
-8.2
ROE
-32.0%
Margin Laba Bersih
-16569.8%
Tentang CRISPR Therapeutics AG - Common Shares Tinjauan perusahaan dari Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Baca selengkapnya
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
CRSP Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$52.77
Kapitalisasi Pasar
$5.06B
P/E (TTM)
-8.2
EPS (TTM)
$-6.47
Pendapatan (TTM)
$4M
Imbal Hasil Dividen
—
ROE
-32.0%
D/E Utang/Ekuitas
—
Rentang 52M
$44 – $78
CRSP Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$4M
2016-12-31
→
2025-12-31
EPS
$-6.47
2017-12-31
→
2025-12-31
Arus Kas Bebas
$-346M
2016-12-31
→
2025-12-31
Margin
-16569.8%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
CRSP
Median Rekan
P/E (TTM)
-8.2
—
P/S (TTM)
1441.8
56.3
P/B
2.6
3.0
Price / FCF (Harga / FCF)
-14.6
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
CRSP
Median Rekan
Operating Margin (Margin Operasi)
-18933.7%
—
Net Profit Margin (Margin Laba Bersih)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
CRSP
Median Rekan
Current Ratio (Rasio Lancar)
13.3
6.7
Quick Ratio (Rasio Cepat)
13.2
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
CRSP
Median Rekan
Revenue YoY (Pendapatan YoY)
-90.6%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
43.1%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
37.3%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
CRSP
Median Rekan
CRSP Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
29 analis
- Beli Kuat 6 20,7%
- Beli 11 37,9%
- Tahan 12 41,4%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
18 analis · 2026-08-15
Median
$80.00
Sekarang
$52.77
Rendah
$44.00
Tinggi
$291.00
Target median
$80.00
+51,6%
Target rata-rata
$87.56
+65,9%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.01%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-0.94 | $-1.22 | 0.28% |
| 31 Maret 2026 | $-1.28 | $-1.25 | -0.03% |
| 31 Des. 2025 | $-1.37 | $-1.18 | -0.19% |
| 30 Sep. 2025 | $-1.17 | $-1.29 | 0.12% |
| 30 Juni 2025 | $-1.29 | $-1.45 | 0.16% |
| 31 Maret 2025 | $-1.58 | $-1.28 | -0.30% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 15
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Neraca 25
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Arus Kas 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Likuiditas & Solvabilitas 2
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Efisiensi 2
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Tingkat Pertumbuhan 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 10
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Laporan Laba Rugi 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Neraca 25
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Arus Kas 11
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Profitabilitas 7
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Likuiditas & Solvabilitas 2
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Efisiensi 2
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Valuasi (TTM) 10
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $4M | $37M | $371M | $1M | $915M |
| Margin Operasi % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Laba Bersih | $-582M | $-366M | $-154M | $-650M | $378M |
| EPS Dilusian | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rasio Lancar | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Rasio Cepat | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-346M | $-145M | $-270M | $-533M | $457M |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- Akses Biaya CRISPR Therapeutics Sangat Murah -- Ini Alasnya Analis Merasakan Potensi Naik 437%
- Kemampuan Pertumbuhan Mega-Cap atau Potensi Pertumbuhan Kecil-Cap? VUG vs. VBK
- 1 Analis Top Wall Street Berpikir CRISPR Therapeutics Bisa Naik Lebih dari Dua Kali Lipat. Haruskah Anda Membeli Sahamnya Secara Besar-besaran?
- Arus Keluar ETF Tercatat - ARKK, CRSP, TEM, HOOD
- Biotech Ini Memiliki Pipeline yang Dapat Mendefinisikan Ulang Seluruh Area Terapeutiknya
- Cathie Wood Berburu Barang Murah: 2 Saham yang Baru Saja Dibeli
- Apakah Saham Biotech Ini Kesempatan Terbaik Anda untuk Membangun Posisi yang Menghasilkan Jutawan?
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 573 pengaju · $3.3B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 89 (0 vs Kuartal sebelumnya) | 47 (-13 vs Kuartal sebelumnya) | 148 (-24 vs Kuartal sebelumnya) | 145 (+21 vs Kuartal sebelumnya) | +5.4M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| ARK Investment Management LLC | $515.999.631 | 9.460.939 | 15,58% | Saham |
| Orbis Allan Gray Ltd | $296.334.582 | 5.433.344 | 8,95% | Saham |
| Capital World Investors | $259.039.094 | 4.749.525 | 7,82% | Saham |
| STATE STREET CORP | $235.703.664 | 4.321.666 | 7,12% | Saham |
| GSK plc | $175.652.997 | 3.220.627 | 5,30% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $117.453.717 | 2.153.015 | 3,55% | Saham |
| SR One Capital Management, LP | $111.194.134 | 2.038.763 | 3,36% | Saham |
| TWO SIGMA INVESTMENTS, LP | $108.459.389 | 1.988.621 | 3,27% | Saham |
| Sumitomo Mitsui Trust Group, Inc. | $93.848.832 | 1.720.734 | 2,83% | Saham |
| Amova Asset Management Americas, Inc. | $93.762.487 | 1.720.097 | 2,83% | Saham |
| EcoR1 Capital, LLC | $75.771.113 | 1.389.276 | 2,29% | Saham |
| Capital International Investors | $69.178.918 | 1.268.407 | 2,09% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $64.457.935 | 1.181.847 | 1,95% | Saham |
| NEA Management Company, LLC | $57.734.408 | 1.058.570 | 1,74% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57.694.430 | 1.057.837 | 1,74% | Saham |
| FMR LLC | $53.577.751 | 982.357 | 1,62% | Saham |
| D. E. Shaw & Co., Inc. | $48.748.506 | 893.812 | 1,47% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35.380.807 | 648.713 | 1,07% | Saham |
| UBS Group AG | $32.419.612 | 594.419 | 0,98% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $31.089.982 | 570.040 | 0,94% | Saham |
| VANGUARD GROUP INC | $27.714.225 | 528.494 | 0,84% | Saham |
| CITADEL ADVISORS LLC | $25.404.514 | 465.796 | 0,77% | Saham |
| BANK OF AMERICA CORP /DE/ | $23.509.740 | 431.055 | 0,71% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.298.288 | 427.178 | 0,70% | Saham |
| MILLENNIUM MANAGEMENT LLC | $20.836.025 | 382.032 | 0,63% | Saham |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20.833.789 | 381.991 | 0,63% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.456.336 | 338.400 | 0,56% | Opsi jual |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17.763.678 | 325.700 | 0,54% | Opsi beli |
| Logos Global Management LP | $16.362.000 | 300.000 | 0,49% | Saham |
| CITADEL ADVISORS LLC | $15.822.054 | 290.100 | 0,48% | Opsi jual |
| Squarepoint Ops LLC | $15.641.472 | 286.789 | 0,47% | Saham |
| NORGES BANK | $14.767.032 | 270.756 | 0,45% | Saham |
| CITADEL ADVISORS LLC | $13.973.148 | 256.200 | 0,42% | Opsi beli |
| GOLDMAN SACHS GROUP INC | $12.748.193 | 233.740 | 0,38% | Saham |
| JANE STREET GROUP, LLC | $12.566.016 | 230.400 | 0,38% | Opsi beli |
| PEAK6 LLC | $11.633.382 | 213.300 | 0,35% | Opsi jual |
| Swiss National Bank | $9.228.168 | 169.200 | 0,28% | Saham |
| Susquehanna Portfolio Strategies, LLC | $8.945.978 | 164.026 | 0,27% | Saham |
| TWO SIGMA ADVISERS, LP | $8.516.256 | 162.400 | 0,26% | Saham |
| LPL Financial LLC | $8.376.280 | 153.581 | 0,25% | Saham |
| Bank of New York Mellon Corp | $8.337.366 | 152.867 | 0,25% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $8.301.261 | 152.205 | 0,25% | Saham |
| Versant Venture Management, LLC | $8.117.243 | 148.831 | 0,25% | Saham |
| Pictet Asset Management Holding SA | $7.989.776 | 142.213 | 0,24% | Saham |
| Life Cycle Investment Partners Ltd | $7.836.962 | 143.692 | 0,24% | Saham |
| TD Asset Management Inc | $7.777.513 | 142.602 | 0,23% | Saham |
| AMERICAN CENTURY COMPANIES INC | $7.606.257 | 139.462 | 0,23% | Saham |
| RAYMOND JAMES FINANCIAL INC | $7.230.750 | 132.577 | 0,22% | Saham |
| RHUMBLINE ADVISERS | $6.627.197 | 121.511 | 0,20% | Saham |
| SFE Investment Counsel | $6.229.434 | 16.700 | 0,19% | Opsi jual |
| Private Advisor Group, LLC | $6.060.980 | 111.129 | 0,18% | Saham |
| EverSource Wealth Advisors, LLC | $6.032.669 | 110.610 | 0,18% | Saham |
| CONGRESS ASSET MANAGEMENT CO | $5.969.567 | 109.453 | 0,18% | Saham |
| BlackRock, Inc. | $5.937.061 | 108.857 | 0,18% | Saham |
| D. E. Shaw & Co., Inc. | $5.901.228 | 108.200 | 0,18% | Opsi beli |
| Campbell & CO Investment Adviser LLC | $5.864.632 | 107.529 | 0,18% | Saham |
| JANE STREET GROUP, LLC | $5.852.142 | 107.300 | 0,18% | Opsi jual |
| California Public Employees Retirement System | $5.599.567 | 102.669 | 0,17% | Saham |
| CAPITAL INTERNATIONAL SARL | $5.521.521 | 101.238 | 0,17% | Saham |
| Affinity Asset Advisors, LLC | $5.454.000 | 100.000 | 0,16% | Saham |
| ALLIANCEBERNSTEIN L.P. | $5.439.011 | 114.337 | 0,16% | Saham |
| CLOUGH CAPITAL PARTNERS L P | $5.363.300 | 98.337 | 0,16% | Saham |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5.172.465 | 94.838 | 0,16% | Saham |
| Slow Capital, Inc. | $5.066.439 | 92.894 | 0,15% | Saham |
| CAPITAL FUND MANAGEMENT S.A. | $4.867.258 | 89.242 | 0,15% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4.815.606 | 101.232 | 0,15% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $4.720.437 | 86.550 | 0,14% | Saham |
| GROUP ONE TRADING LLC | $4.638.082 | 85.040 | 0,14% | Saham |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4.575.742 | 83.897 | 0,14% | Saham |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4.502.113 | 82.547 | 0,14% | Saham |
| Concurrent Investment Advisors, LLC | $4.497.728 | 82.467 | 0,14% | Saham |
| WELLS FARGO & COMPANY/MN | $4.309.151 | 79.009 | 0,13% | Saham |
| Fisher Asset Management, LLC | $4.251.957 | 77.960 | 0,13% | Saham |
| Trexquant Investment LP | $4.225.268 | 77.471 | 0,13% | Saham |
| COMMONWEALTH EQUITY SERVICES, LLC | $4.194.122 | 76.900 | 0,13% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $4.055.652 | 73.847 | 0,12% | Saham |
| Man Group plc | $3.992.001 | 73.194 | 0,12% | Saham |
| PEAK6 LLC | $3.834.162 | 70.300 | 0,12% | Opsi beli |
| ENVESTNET ASSET MANAGEMENT INC | $3.822.196 | 70.081 | 0,12% | Saham |
| ALGERT GLOBAL LLC | $3.593.095 | 65.880 | 0,11% | Saham |
| Walleye Trading LLC | $3.528.738 | 64.700 | 0,11% | Opsi jual |
| MILLENNIUM MANAGEMENT LLC | $3.146.958 | 57.700 | 0,10% | Opsi beli |
| CAPITAL INTERNATIONAL LTD /CA/ | $3.057.840 | 56.066 | 0,09% | Saham |
| NOMURA HOLDINGS INC | $3.055.713 | 56.027 | 0,09% | Saham |
| Rafferty Asset Management, LLC | $3.045.132 | 55.833 | 0,09% | Saham |
| Green Alpha Advisors, LLC | $3.043.550 | 55.804 | 0,09% | Saham |
| Walleye Trading LLC | $3.005.154 | 55.100 | 0,09% | Opsi beli |
| Caption Management, LLC | $2.999.700 | 55.000 | 0,09% | Opsi beli |
| MetLife Investment Management, LLC | $2.958.413 | 54.243 | 0,09% | Saham |
| BENJAMIN EDWARDS INC | $2.956.845 | 54.216 | 0,09% | Saham |
| Quantinno Capital Management LP | $2.869.349 | 52.610 | 0,09% | Saham |
| Cetera Investment Advisers | $2.856.133 | 52.368 | 0,09% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.788.521 | 51.128 | 0,08% | Saham |
| CITIGROUP INC | $2.781.540 | 51.000 | 0,08% | Opsi beli |
| CITIGROUP INC | $2.781.540 | 51.000 | 0,08% | Opsi jual |
| WOLVERINE ASSET MANAGEMENT LLC | $2.727.000 | 50.000 | 0,08% | Opsi jual |
| OSAIC HOLDINGS, INC. | $2.693.150 | 49.381 | 0,08% | Saham |
| Privium Fund Management B.V. | $2.452.882 | 44.974 | 0,07% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $2.394.306 | 43.900 | 0,07% | Saham |
| TUDOR INVESTMENT CORP ET AL | $2.318.604 | 42.512 | 0,07% | Saham |
Orang dalam perusahaan 32 orang dalam · 12 pejabat · 16 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 Maret 2026 M | 255.501 | 0 | 9 | $-10.756.932 |
| Brendan Smith | Chief Financial Officer | 18 Feb. 2023 M | 5.072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 Maret 2021 M | 1.891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 Maret 2025 M | 10.544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 Agu 2022 A | 26.797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 29 Mei 2026 A | 19.357 | 1 | 2 | $-312.892 |
| James R. Kasinger | General Counsel and Secretary | 29 Mei 2026 A | 94.308 | 0 | 5 | $-645.902 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 Okt. 2023 A | 4.411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 3 Des. 2021 M | 52.364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 Jan. 2018 M | 25.204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 Juni 2017 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 Okt. 2016 C | 505.617 | 0 | 0 | $0 |
| Christian Rommel | Direktur | 5 Juni 2026 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | Direktur | 5 Juni 2026 A | — | 0 | 0 | $0 |
| Douglas A Treco | Direktur | 5 Juni 2026 A | — | 0 | 0 | $0 |
| Briggs Morrison | Direktur | 5 Juni 2026 A | — | 0 | 0 | $0 |
| Katherine A High | Direktur | 5 Juni 2026 A | — | 0 | 0 | $0 |
| Ali Behbahani | Direktur | 5 Juni 2026 A | 14 | 0 | 0 | $0 |
| John Greene | Direktur | 5 Juni 2026 A | 7.000 | 0 | 0 | $0 |
| Simeon George | Direktur | 5 Juni 2026 A | 1.730.179 | 0 | 0 | $0 |
| Maria Fardis | Direktur | 5 Juni 2026 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | Direktur | 5 Juni 2026 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Direktur | 9 Juni 2022 A | 148.831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Direktur | 19 Nov. 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Direktur | 18 Des. 2018 S | 1.171.268 | 0 | 0 | $0 |
| Thomas Woiwode | Direktur | 15 Juni 2018 A | 640.014 | 0 | 0 | $0 |
| Anthony N Coles | Direktur | 31 Mei 2017 A | 70.000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Pemilik 10% | 4 Des. 2017 S | 3.722.534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | Pemilik 10% | 24 Okt. 2016 C | 744.380 | 0 | 0 | $0 |
| GSK plc | Pemilik 10% | 24 Okt. 2016 C | 3.220.627 | 0 | 0 | $0 |
| Raju Prasad | — | 7 Agu 2026 G | 14.815 | 0 | 10 | $-5.100.841 |
| Rodger Novak | — | 30 Juni 2021 S | 573.007 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 6 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 pengajuan | 16 Feb. 2021 | — | Pengajuan awal | — | SEC |
| GlaxoSmithKline plc ×5 pengajuan | 10 Juli 2020 | — | Pengajuan awal | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 pengajuan | 4 Feb. 2020 | — | Pengajuan awal | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 pengajuan | 7 Juni 2019 | — | Pengajuan awal | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 pengajuan | 8 Feb. 2018 | — | Pengajuan awal | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 pengajuan | 16 Jan. 2018 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 32 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| GNOM · Global X Funds | 3,85% | 38.191 NS | 31 Mei 2026 | N-PORT |
| IDNA · iShares Trust | 1,63% | 62.247 SH | 8 Agu 2026 | Harian |
| LABU · Direxion Shares ETF Trust | 0,98% | 97.235 NS | 30 April 2026 | N-PORT |
| IBB · iShares Trust | 0,36% | 658.537 SH | 8 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 5.248 SH | 8 Agu 2026 | Harian |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70.696 SH | 8 Agu 2026 | Harian |
| IWN · iShares Trust | 0,27% | 752.223 SH | 8 Agu 2026 | Harian |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,21% | 104.016 NS | 31 Mei 2026 | N-PORT |
| ISCV · iShares Trust | 0,15% | 20.568 SH | 8 Agu 2026 | Harian |
| IWM · iShares Trust | 0,15% | 2.353.025 SH | 8 Agu 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536.446 SH | 8 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,15% | 39.589 NS | 30 April 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,10% | 6.636 SH | 8 Agu 2026 | Harian |
| ISCB · iShares Trust | 0,07% | 4.136 SH | 8 Agu 2026 | Harian |
| SMLF · iShares Trust | 0,07% | 57.970 SH | 8 Agu 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1.106.455 SH | 8 Agu 2026 | Harian |
| ESML · iShares Trust | 0,06% | 33.283 SH | 8 Agu 2026 | Harian |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,06% | 108 NS | 31 Mei 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 5.486 SH | 8 Agu 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13.170 SH | 8 Agu 2026 | Harian |
| IWO · iShares Trust | 0,04% | 109.974 SH | 8 Agu 2026 | Harian |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1.736 SH | 8 Agu 2026 | Harian |
| XT · iShares Trust | 0,03% | 21.837 SH | 8 Agu 2026 | Harian |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,03% | 3.509 NS | 31 Mei 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7.774 SH | 8 Agu 2026 | Harian |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20.627 SH | 8 Agu 2026 | Harian |
| IYY · iShares Trust | 0,01% | 4.231 SH | 8 Agu 2026 | Harian |
| ITOT · iShares Trust | 0,01% | 128.511 SH | 8 Agu 2026 | Harian |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,01% | 15.609 NS | 31 Mei 2026 | N-PORT |
| IWV · iShares Trust | 0,01% | 25.457 SH | 8 Agu 2026 | Harian |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 289 NS | 31 Mei 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75.392 SH | 8 Agu 2026 | Harian |